Dr. Nakamura’s position in the Japan medical profession and understanding of local medical practice will be a valuable near-term source of advice and guidance as we move toward the launch of NC-stat DPNCheck in the Japanese market during 2014.
The NeuroMetrix press release stated: "Dr. Nakamura is considered a leader in the field of diabetes research and treatment." I find this believable; consequently, I find it difficult to believe Dr. Nakamura would become associated with a losing company.
NURO closed on 02014.01.17 at $2.61. 52-week range: $1.47 - $4.25.
No comments:
Post a Comment